Correlation Between Champions Oncology and Opthea

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Champions Oncology and Opthea at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Champions Oncology and Opthea into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Champions Oncology and Opthea, you can compare the effects of market volatilities on Champions Oncology and Opthea and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Champions Oncology with a short position of Opthea. Check out your portfolio center. Please also check ongoing floating volatility patterns of Champions Oncology and Opthea.

Diversification Opportunities for Champions Oncology and Opthea

0.39
  Correlation Coefficient

Weak diversification

The 3 months correlation between Champions and Opthea is 0.39. Overlapping area represents the amount of risk that can be diversified away by holding Champions Oncology and Opthea in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Opthea and Champions Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Champions Oncology are associated (or correlated) with Opthea. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Opthea has no effect on the direction of Champions Oncology i.e., Champions Oncology and Opthea go up and down completely randomly.

Pair Corralation between Champions Oncology and Opthea

Given the investment horizon of 90 days Champions Oncology is expected to generate 0.81 times more return on investment than Opthea. However, Champions Oncology is 1.23 times less risky than Opthea. It trades about 0.04 of its potential returns per unit of risk. Opthea is currently generating about 0.0 per unit of risk. If you would invest  862.00  in Champions Oncology on December 29, 2024 and sell it today you would earn a total of  49.00  from holding Champions Oncology or generate 5.68% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy86.89%
ValuesDaily Returns

Champions Oncology  vs.  Opthea

 Performance 
       Timeline  
Champions Oncology 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Champions Oncology are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak fundamental drivers, Champions Oncology reported solid returns over the last few months and may actually be approaching a breakup point.
Opthea 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Opthea has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Opthea is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Champions Oncology and Opthea Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Champions Oncology and Opthea

The main advantage of trading using opposite Champions Oncology and Opthea positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Champions Oncology position performs unexpectedly, Opthea can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opthea will offset losses from the drop in Opthea's long position.
The idea behind Champions Oncology and Opthea pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bonds Directory
Find actively traded corporate debentures issued by US companies